Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz, M., Bedke, J., Bögemann, M., Grimm, M.-O., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Lehmann, J., Indorf, M., Frank, M., Bokemeyer, C., Gschwend, J.E., 2019.

Eur J Canc 107, 37–45. doi:10.1016/j.ejca.2018.11.001

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: European Journal of Cancer
SWITCH II
2018
Prophylaxis of Chemotherapy-Induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in 2489 Cancer Patients: Final Results from the Non-Interventional Study NADIR

Fietz, T., Lück, A., Schulz, H., Harde, J., Losem, C., Grebhardt, S., Wolff, T., Potthoff, K., Müller, U., Zaiss, M., Kurbacher, C.M.

Current Medical Research and Opinion, 17. Dezember 2018, 1–27. https://doi.org/10.1080/03007995.2018.1560200.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Current Medical Research and Opinion
NADIR
2018
Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia.

Decker, T., Mündlein, A., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Hegewisch-Becker, S., Lerchenmüller, C., 2018.

Ann Oncol 29(suppl_8), 295P. doi:https://doi.org/10.1093/annonc/mdy272.285

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
VICTORIA
2018
Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study.

Welslau, M.K., Zaiss, M., Söling, U., Untch, M., Müller, L., Lüftner, D., Meiler, J., Welt, A., Sahlmann, J., Houet, L., Runkel, E., Marschner, N.W., 2018.

Ann Oncol 29(suppl_8), 341P. doi:10.1093/annonc/mdy272.331

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
INGE-B
2018
Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Bernhardt, C., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Rittmeyer, A., Bischoff, H., Waller, C., Sebastian, M., Thomas, M., 2018.

Ann Oncol, 43rd ESMO Congress 29 (suppl 8)(1428P). doi:https://doi.org/10.1093/annonc/mdy292.050

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2018
Prospective real world data of an ongoing post-authorization safety study on idelalisib in patients with CLL and refractory FL.

Hoechstetter, M., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Ramroth, H., Rummel, M., 2018.

Oncol Res Treat 41 (suppl 4) (P534), 173.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
IDELA
2018
Molekulare Testung, Häufigkeiten molekularer Alterationen und zielgerichtete Erstlinientherapie bei Patienten mit Nicht-kleinzelligem Lungenkarzinom in Deutschland. Ergebnisse der prospektiven Registerplattform CRISP (AIO-TRK-0315)

Griesinger, F.

Oncol Res Treat 41

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2018
Real World Molecular Testing in Patients with EGFR Mutation-Positive Locally Advanced or Advanced NSCLC in routine practice in Germany – Interim results of the clinical registry PANORAMA.

Griesinger, F., Büttner, R., Deppermann, K.-M., Reinmuth, N., Schütte, W., Thomas, M., Wroblewski, M., Schumann, C., 2018.

Oncol Res Treat 2018;41(suppl 4): V753, S.249

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PANORAMA
2018
Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial vicTORia.

Decker, T., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Lerchenmüller, C., 2018.

Oncol Res Treat 41 (suppl4)(V491), 158–159.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
VICTORIA
2018
Everolimus as second-line therapy for metastatic renal cell carcinoma: final results of phase IV study MARC-2.

M. Staehler, D. Christoph, M. Stöckle, J. Harde, A. Stenzl, D. Klein, I. Benz-Rüd, V. Grünwald, 2018.

Oncol Res Treat 41 (suppl 4)(P610).

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MARC-2
2018